Narrowband (312-nm) UV-B suppresses interferon γ and interleukin (IL) 12 and increases IL-4 transcripts: Differential regulation of cytokines at the single-cell level

Archives of Dermatology

Volumn 139, Issue 2, 2003, Pages 155-161

  Walters, Ian B ^a   Ozawa, Maki ^a   Cardinale, Irma ^a   Gilleaudeau, Patricia ^a   Trepicchio, William L ^a   Bliss, Judith ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; MESSENGER RNA;

ADULT; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEVICE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; RADIATION DOSE; RNA ANALYSIS; SKIN BIOPSY; SPECTRAL SENSITIVITY; T LYMPHOCYTE; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ADULT; AGED; BASE SEQUENCE; BIOPSY, NEEDLE; CELLS, CULTURED; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROGNOSIS; PROSPECTIVE STUDIES; PSORIASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; ULTRAVIOLET THERAPY;

EID: 0037319925     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.2.155     Document Type: Article

References (47)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1-26.
2. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, IFN-γ, IL-2, and TNF-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999;113:752-759.
3. Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol. 1999;140(suppl 54):1-7.
4. Trepicchio WL, Ozawa M, Walters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999;104:1527-1537.
5. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111:1053-1057.
6. Ullrich S. The role of epidermal cytokines in the generation of cutaneous immune reactions and ultraviolet radiation-induced immune suppression. Photochem Photobiol. 1995;62:389-401.
7. Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J. 2001;1:272-287.
8. Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG. Narrowband UV-B produces superior clinical and histopathological resolution of moderateto-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997;133:1514-1522.
9. An appraisal of narrowband (TL-01) UVB phototherapy: British Photodermatology Group Workshop Report (April 1996). Br J Dermatol. 1997;137:327-330.
10. Walters IB, Burack LH, Coven TR, Gilleaudeau P, Krueger JG. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol. 1999;40:893-900.
11. van Weelden H, Baart de la Faille H, Young E, van der Leun JC. A new development in UVB phototherapy of psoriasis. Br J Dermatol. 1988;119:11-19.
12. Ferguson J. The use of narrowband UV-B (tube lamp) in the management of skin disease. Arch Dermatol. 1999;135:589-590.
13. Halasz CLG. Narrowband UVB phototherapy for psoriasis. Photodermatol Photoimmunol Photomed. 1999;15:81-84.
14. Wainwright NJ, Dawe RS, Ferguson J. Narrowband ultraviolet B (TL-01) phototherapy for psoriasis. Br J Dermatol. 1998;139:410-414.
15. Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol. 1999;135:1377-1380.
16. Ozawa M, Ferenczi K, Kikuchi T, et al. 312-nanometer ultraviolet B light (narrowband UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med. 1999;189:711-718.
17. Morita A, Werfel T, Stege H, et al. Evidence that single oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med. 1997;186:1763-1768.
18. Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol. 1981;77:13-19.
19. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138-146.
20. Cooper KD. Cell-mediated immunosuppressive mechanisms induced by UV radiation. Photochem Photobiol. 1996;63:400-406.
21. Duthie MS, Kimber I, Norval M. The effects of ultraviolet radiation on the human immune system. Br J Dermatol. 1999;140:995-1009.
22. Krutmann J, Morita A. Mechanisms of ultraviolet (UV) B and UVA phototherapy. J Investig Dermatol Symp Proc. 1999;4:70-72.
23. Takashima A, Bergstresser PR. Impact of UVB radiation on the epidermal cytokine network. Photochem Photobiol. 1996;63:397-400.
24. Scordi IA, Vincek V. Timecourse study of UVB-induced cytokine induction in whole mouse skin. Photodermatol Photoimmunol Photomed. 2000;16:67-73.
25. Skov L, Hansen H, Dittmar HC, Barker JN, Simon JC, Baadsgaard O. Susceptibility to effects of UVB irradiation on induction of contact sensitivity, relevance of number and function of Langerhans cells and epidermal macrophages. Photochem Photobiol. 1998;67:714-719.
26. Krutmann J. Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy. J Photochem Photobiol B. 1998;44:159-164.
27. Kang K, Gilliam AC, Chen G, Tootell E, Cooper KD. In human skin, UVB initiates early induction of IL-10 over IL-12 preferentially in the expanding dermal monocytic/macrophagic population. J Invest Dermatol. 1998;110:31-38.
28. Di Nuzzo S, Sylva-Steenland RMR, Koomen CW, et al. UVB radiation induces expression of interleukin-4 in normal human skin, and favors the development of type 2 responses in dermal T cells. In: Di Nuzzo S, ed. Effects of Ultraviolet Radiation on Cutaneous T Cells [doctoral thesis]. Amsterdam, the Netherlands: University of Amsterdam; 2000:77-99.
29. Yoshida Y, Kang K, Chen G, Gilliam AC, Cooper KD. Cellular fibronectin is induced in ultraviolet-exposed human skin and induces IL-10 production by monocytes/macrophages. J Investig Dermatol Symp Proc. 1999;113:49-55.
30. + macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein. J Immunol. 1994;153:5256-5264.
31. Jones CD, Guckian M, El-Ghorr AA, Gibbs NK, Norval M. Effects of phototherapy on the production of cytokines by peripheral blood mononuclear cells and on systemic antibody responses in patients with psoriasis. Photodermatol Photoimmunol Photomed. 1996;12:204-210.
32. Szabo SK, Hammerberg C, Bata-Csorgo ZS, Cooper KD, Szent-Gyorgyi A. The mechanism of action of UVB in psoriasis: rapidly decreased T cell numbers and preferential reduction of interferon γ (IFNγ) production [abstract]. J Investig Dermatol Symp Proc. 1997;108:558.
33. Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, Cooper KD. Identification and quantitation of interferon-γ producing T cells in psoriatic lesions. J Investig Dermatol Symp Proc. 1998;111:1072-1078.
34. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon-γ. J Immunol. 1986;137:245-254.
35. Barker JN, Goodlad JR, Yu CC, Groves RW, MacDonald DM. Increased epidermal cell proliferation in normal human skin in vivo following local administration of interferon-γ. Am J Pathol. 1993;142:1091-1097.
36. Bianchi M, Meng C, Ivashkiv LB. Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids. Proc Natl Acad Sci USA. 2000;97:9573-9578.
37. Aragane Y, Kulms D, Luger TA, Schwarz T. Down-regulation of interferon γ-activated STAT1 by UV light. Proc Natl Acad Sci U S A. 1997;94:11490-11495.
38. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-γ. Annu Rev Immunol. 1997;15:749-795.
39. Reich K, Bruck M, Grafe A, Vente C, Neumann C, Garbe C. Treatment of psoriasis with interleukin-10. J Investig Dermatol Symp Proc. 1998;111:1235-1236.
40. Krueger JG, Walters IB, Miyazawa M, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-TAC antibody to patients with psoriasis. J Am Acad Dermatol. 2000;43:448-452.
41. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol. 2002;138:591-600.
42. Lohner ME, Krueger G, Gottlieb A, et al. Clinical trials of a fully human anti-IL8 antibody for the treatment of psoriasis [abstract]. Br J Dermatol. 1999;141:989. Abstract 76.
43. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation. 1994;58:602-610.
44. Varadhachary AS, Perdow SN, Hu C, Ramanarayanan M, Salgame P. Differential ability of T cell subsets to undergo activation-induced cell death. Proc Natl Acad Sci U S A. 1997;94:5778-5783.
45. Reiner SL, Seder RA. Dealing from the evolutionary pawnshop: how lymphocytes make decisions. Immunity. 1999;11:1-10.
46. Chavin KD, Qin L, Yon R, Lin J, Yagita H, Bromberg JS. Anti-CD2 mAbs suppress cytotoxic lymphocyte activity by the generation of Th2 suppressor cells and receptor blockade. J Immunol. 1994;152:3729-3739.
47. Ghoreschi K, Thomas P, Breit S, et al. Interleukin 4-induced immune deviation as therapy for psoriasis [abstract]. J Investig Dermatol Symp Proc. 2001;117:465.